Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 July 2019
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC